OM:MOB

Stock Analysis Report

Executive Summary

Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products for skin diseases in Sweden, the United States, and internationally.

Snowflake

Fundamentals

Proven track record with imperfect balance sheet.

Risks

  • Moberg Pharma is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has Moberg Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-2.7%

OM:MOB

-5.2%

SE Pharmaceuticals

-1.2%

SE Market


1 Year Return

23.9%

OM:MOB

-8.3%

SE Pharmaceuticals

-2.6%

SE Market

MOB outperformed the Pharmaceuticals industry which returned -8.3% over the past year.

MOB outperformed the Market in Sweden which returned -2.7% over the past year.


Share holder returns

MOBIndustryMarket
7 Day-2.7%-5.2%-1.2%
30 Day-6.6%-4.0%-3.6%
90 Day-6.1%-5.8%-2.8%
1 Year23.9%23.9%-6.5%-8.3%1.4%-2.6%
3 Year51.8%51.8%13.3%9.3%25.3%6.6%
5 Year100.6%100.6%-13.9%-19.8%44.9%14.3%

Price Volatility Vs. Market

How volatile is Moberg Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Moberg Pharma undervalued based on future cash flows and its price relative to the stock market?

36.57x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Moberg Pharma to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Moberg Pharma to establish if it is available at substantial discount.


Price Based on Earnings

Moberg Pharma is overvalued based on earnings compared to the Europe Pharmaceuticals industry average.

Moberg Pharma is overvalued based on earnings compared to the Sweden market.


Price Based on Expected Growth

Moberg Pharma earnings are not expected to grow next year, we can't assess if its growth is good value.


Price Based on Value of Assets

Moberg Pharma is good value based on assets compared to the SE Pharmaceuticals industry average.


Next Steps

Future Growth

How is Moberg Pharma expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

-65.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Moberg Pharma's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.

Moberg Pharma's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.

Moberg Pharma's revenues are expected to decrease over the next 1-3 years, this is below the Sweden market average.

Moberg Pharma's earnings are expected to decrease over the next 1-3 years, this is below the Sweden market average.

Moberg Pharma's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 0.4%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Moberg Pharma will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has Moberg Pharma performed over the past 5 years?

7.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Moberg Pharma's year on year earnings growth rate has been positive over the past 5 years.

Moberg Pharma's 1-year earnings growth exceeds its 5-year average (389.8% vs 7.9%)

Moberg Pharma's earnings growth has exceeded the Europe Pharmaceuticals industry average in the past year (389.8% vs 5.4%).


Return on Equity

Moberg Pharma has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Moberg Pharma used its assets less efficiently than the Europe Pharmaceuticals industry average last year based on Return on Assets.


Return on Capital Employed

Moberg Pharma has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Moberg Pharma's financial position?


Financial Position Analysis

Moberg Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Moberg Pharma's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Moberg Pharma's level of debt (58.8%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (12.8% vs 58.8% today).

Debt is not well covered by operating cash flow (13.6%, less than 20% of total debt).

Interest payments on debt are not well covered by earnings (EBIT is 1.6x annual interest expense, ideally 3x coverage).


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 2.5x debt.


Next Steps

Dividend

What is Moberg Pharma's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Moberg Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Moberg Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Moberg Pharma has not reported any payouts.

Unable to verify if Moberg Pharma's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Moberg Pharma has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Moberg Pharma's salary, the management and board of directors tenure and is there insider trading?

0.6yrs

Average management tenure


CEO

Anna Ljung (39yo)

0.3yrs

Tenure

Ms. Anna Ljung, M.Sc., BA has been Chief Executive Officer of Moberg Pharma AB (publ) since May 2019. Ms. Ljung served as the Chief Financial Officer at Moberg Pharma AB (publ) (alternate name: Moberg Derm ...


Management Age and Tenure

0.6yrs

Average Tenure

39yo

Average Age

The average tenure for the Moberg Pharma management team is less than 2 years, this suggests a new team.


Board Age and Tenure

0.3yrs

Average Tenure

51yo

Average Age

The average tenure for the Moberg Pharma board of directors is less than 3 years, this suggests a new board.


Insider Trading

Information is not available.


Recent Insider Transactions

Sellkr130,20827 Jun 19
Anna Ljung
EntityIndividual
Role
Chief Executive Officer
Shares1,994
Max Pricekr65.30
Buykr130,00927 Jun 19
Anna Ljung
EntityIndividual
Role
Chief Executive Officer
Shares1,994
Max Pricekr65.20

Ownership Breakdown


Management Team

  • Peter Wolpert (50yo)

    Co-Founder & Executive Chairman

    • Tenure: 13.4yrs
    • Compensation: SEK4.71m
  • Marie Moberg

    Co-Founder

    • Tenure: 13.4yrs
    • Compensation: SEK193.70k
  • Anna Ljung (39yo)

    Chief Executive Officer

    • Tenure: 0.3yrs
  • Gunilla Wengström

    Senior Director of Sales & Marketing

    • Tenure: 0.6yrs
  • Sarah Hellerfelt (37yo)

    Chief Financial Officer

    • Tenure: 0.3yrs

Board Members

  • Lennart Emtestam

    Member of Scientific Advisory Board

  • Jan Faergemann

    Member of Scientific Advisory Board

  • Johan Heilborn

    Member of Scientific Advisory Board

  • Howard Maibach

    Member of Scientific Advisory Board

  • Peter Wolpert (50yo)

    Co-Founder & Executive Chairman

    • Tenure: 0.3yrs
    • Compensation: SEK4.71m
  • Bernt Lindelöf

    Member of Scientific Advisory Board

  • Andrew Hochman

    Director

    • Tenure: 0.4yrs
  • Mattias Klintemar (52yo)

    Director

    • Tenure: 4.3yrs
    • Compensation: SEK222.00k
  • Fredrik Granstrom (51yo)

    Director

    • Tenure: 0.3yrs

Company Information

Moberg Pharma AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Moberg Pharma AB (publ)
  • Ticker: MOB
  • Exchange: OM
  • Founded: 2006
  • Industry: pharmaceuticals
  • Sector: pharmaceuticals & biotech
  • Market Cap: kr1.199b
  • Shares outstanding: 18.67m
  • Website: Click here

Number of Employees


Location

  • Moberg Pharma AB (publ)
  • Gustavslundsvägen 42
  • 5th Floor
  • Bromma
  • Stockholm County
  • 167 51
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MOBOM (OMX Nordic Exchange Stockholm)YesOrdinary SharesSESEKMay 2011
0P48LSE (London Stock Exchange)YesOrdinary SharesGBSEKMay 2011
MB8DB (Deutsche Boerse AG)YesOrdinary SharesDEEURMay 2011
MBGR.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDMay 2011

Biography

Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products for skin diseases in Sweden, the United States, and internationally. It develops MOB-015, which is under Phas ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/17 21:24
End of Day Share Price2019/08/16 00:00
Earnings2019/03/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.